These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26031358)

  • 1. A review of statistical designs for improving the efficiency of phase II studies in oncology.
    Wason JM; Jaki T
    Stat Methods Med Res; 2016 Jun; 25(3):1010-21. PubMed ID: 26031358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
    Mossop H; Grayling MJ; Gallagher FA; Welsh SJ; Stewart GD; Wason JMS
    Br J Cancer; 2022 Feb; 126(2):204-210. PubMed ID: 34750494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.
    Lin CJ; Wason JMS
    Stat Med; 2017 Dec; 36(29):4616-4626. PubMed ID: 28850689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive designs for single-arm phase II trials in oncology.
    Englert S; Kieser M
    Pharm Stat; 2012; 11(3):241-9. PubMed ID: 22411839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the flexibility and efficiency of phase II designs for oncology trials.
    Englert S; Kieser M
    Biometrics; 2012 Sep; 68(3):886-92. PubMed ID: 22150825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues in oncology drug development, with a focus on Phase II trials.
    Sargent DJ; Taylor JM
    J Biopharm Stat; 2009; 19(3):556-62. PubMed ID: 19384696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An exact method for analysis following a two-stage phase II cancer clinical trial.
    Jovic G; Whitehead J
    Stat Med; 2010 Dec; 29(30):3118-25. PubMed ID: 21170906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal and minimax three-stage designs for phase II oncology clinical trials.
    Chen K; Shan M
    Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrated phase II/III clinical trials in oncology: a case study.
    Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
    Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials.
    Englert S; Kieser M
    Stat Med; 2015 Jun; 34(13):2128-37. PubMed ID: 25781860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II cancer clinical trials for biomarker-guided treatments.
    Jung SH
    J Biopharm Stat; 2018; 28(2):256-263. PubMed ID: 28902567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nine-year change in statistical design, profile, and success rates of Phase II oncology trials.
    Ivanova A; Paul B; Marchenko O; Song G; Patel N; Moschos SJ
    J Biopharm Stat; 2016; 26(1):141-9. PubMed ID: 26368744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of two-stage designs of Phase 2 single-arm trials in glioblastoma: a systematic review.
    Yoo W; Kim S; Garcia M; Mehta S; Sanai N
    BMC Med Res Methodol; 2022 Dec; 22(1):327. PubMed ID: 36550391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials.
    Wason JM; Trippa L
    Stat Med; 2014 Jun; 33(13):2206-21. PubMed ID: 24421053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.
    Vickers AJ; Ballen V; Scher HI
    Clin Cancer Res; 2007 Feb; 13(3):972-6. PubMed ID: 17277252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimation of secondary endpoints in two-stage phase II oncology trials.
    Kunz CU; Kieser M
    Stat Med; 2012 Dec; 31(30):4352-68. PubMed ID: 22930470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.